Who is sponsoring NCT03837314?

NCT03837314 is sponsored by North Bristol NHS Trust.

What drugs are being tested in NCT03837314?

Interventions in NCT03837314: Bioinduction "Picostim" Deep Brain Stimulation system.

What condition does NCT03837314 study?

NCT03837314 studies Parkinson's Disease.

Is NCT03837314 still recruiting?

NCT03837314 is currently status unknown. Last updated 30 October 2023.

Last reviewed 2023-10-30 · How we verify

NCT03837314: SPARKS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Simpler and Safer Deep Brain Stimulation for Parkinson's Disease

Status unknown NA Last updated 30 October 2023

What this trial tests

NA trial testing Bioinduction "Picostim" Deep Brain Stimulation system in Parkinson's Disease in 25 participants. Status unknown.

Timeline

28 October 2020

Primary endpoint
1 June 2025

1 January 2026

Quick facts

Lead sponsor	North Bristol NHS Trust
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	28 October 2020
Primary completion	1 June 2025
Estimated completion	1 January 2026
Sites	1 location across United Kingdom

Drugs / interventions tested

Bioinduction "Picostim" Deep Brain Stimulation system

Conditions studied

Parkinson's Disease — all drugs for Parkinson's Disease →

Sponsor

North Bristol NHS Trust — full company profile →

Who can join

21 and older, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim is to improve availability and acceptability of deep brain stimulation (DBS) for the treatment of Parkinson by shortening and simplifying the implantation procedure, thereby reducing time in surgery, complexity, post-surgery complications and cost, and increasing patient satisfaction. To facilitate the shortening and simplifying of the implantation procedure, a miniaturised skull-mounted DBS device (Picostim) has been developed which is optimised to generate waveforms needed for stimulation of the subthalamic nucleus (STN) and STN region, employing a unique method of controlling stimulation current. The planned study is a single centre, open label, non-randomised design with the primary objective of showing similarity in control of motor symptoms for the Picostim device compared with previously published data for existing DBS devices.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Implantable Pulse Generators for Deep Brain Stimulation: Challenges, Complications, and Strategies for Practicality and Longevity.
Sarica C, Iorio-Morin C, Aguirre-Padilla DH, Najjar A, et al · · 2021 · cited 50× · PMID 34512295 · DOI 10.3389/fnhum.2021.708481
DyNeuMo Mk-1: Design and pilot validation of an investigational motion-adaptive neurostimulator with integrated chronotherapy.
Zamora M, Toth R, Morgante F, Ottaway J, et al · · 2022 · cited 29× · PMID 35016994 · DOI 10.1016/j.expneurol.2022.113977
Deep brain-machine interfaces: sensing and modulating the human deep brain.
Sui Y, Yu H, Zhang C, Chen Y, et al · · 2022 · cited 13× · PMID 36644311 · DOI 10.1093/nsr/nwac212
A clinical grade neurostimulation implant for hierarchical control of physiological activity
Benjaber M, Zamora M, Toth R, Fleming JE, et al · · 2025 · DOI 10.1101/2025.10.21.683630

Verify or expand the search:

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07330258 — A US Study That Observes How Parkinson's Disease Changes Over Time in Patients Who Still Have Movement Symptoms Despite · recruiting
NCT07384429 — Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease · Phase 4 · recruiting
NCT07384442 — Effects of Targeted Temporal Interference Stimulation of Cerebellar Nuclei on Tremor and Gait Disturbance in Parkinson's · NA · recruiting
NCT06562569 — Non-invasive VNS for PD Gait · NA · recruiting

Other North Bristol NHS Trust trials

Trials by the same sponsor.

NCT06115044 — The DINE-Normal Proof-of-concept Study · NA · completed
NCT01932593 — Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis · NA · completed
NCT03652363 — GDNF in ideopathicParkinsons Disease · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03837314 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by North Bristol NHS Trust
Last refreshed: 30 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03837314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing